Neogenomics Inc (NASDAQ:NEO)

Data as of Jan 26
 +0.01 / +0.26%
Today’s Change
Today|||52-Week Range
Health Services
Medical/Nursing Services

Company Description

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories to provide genetic and molecular testing services. The company offers various testing services, including Cytogenetics, Fluorescence In-Situ Hybridization, Flow Cytometry, Immunohistochemistry and Molecular testing. It offers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.

Contact Information

NeoGenomics, Inc.
12701 Commonwealth Drive
Fort Myers Florida 33913
P:(239) 768-0600
Investor Relations:
(239) 325-2001



Other institutional43.68%
Individual stakeholders21.79%
Mutual fund holders12.83%

Top Executives

Douglas M. VanOortExecutive Chairman & Chief Executive Officer
Robert J. ShovlinChief Operating Officer
George A. CardozaChief Financial Officer
Maher AlbitarChief Medical Officer
Steven A. RossChief Information Officer

Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer.

Morningstar: © 2015 Morningstar, Inc. All Rights Reserved.

Factset: FactSet Research Systems Inc. 2015. All rights reserved.

Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved.

Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Standard & Poor's and S&P are registered trademarks of Standard & Poor’s Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2015 and/or its affiliates.